Heath CW, Strauss MB, Castle WB. Quantitative aspects of iron deficiency in hypochromic anemia. (The parenteral administration of iron). J Clin Invest. 1932;11:1293–312. https://doi.org/10.1172/JCI100478.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Goetsch AT, Moore CV, Minnich V. Observations on the effect of massive doses of iron given intravenously to patients with hypochromic anemia. Blood. 1946;1:129–42.

CAS  Article  Google Scholar 

Nissim JA. Intravenous administration of iron. Lancet. 1947;2(6463):49–51. https://doi.org/10.1016/s0140-6736(47)90053-6.

CAS  Article  PubMed  Google Scholar 

Nissim JA, Robson JM. Preparation and standardisation of saccharated iron oxide for intravenous administration. Lancet. 1949;1(6556):686–9.

CAS  Article  Google Scholar 

Müller A. Classification and properties of iron preparations. Arzneimittelforschung (Drug Res). 1974;24:880–3.

Google Scholar 

Theil EC, Sayers DE, Brown MA. Similarity of the structure of ferritin and iron.dextran (Imferon) determined by extended X-ray absorption fine structure analysis. J Biol Chem. 1979;254:8132–4.

CAS  Article  Google Scholar 

Auerbach M, MacDougall I. The available intravenous iron formulations: History, efficacy, and toxicology. Hemodial Int. 2017;21(Suppl 1):S83-92. https://doi.org/10.1111/hdi.12560.

Article  PubMed  Google Scholar 

Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. J Am Med Assoc. 1980;243:1726–31.

CAS  Article  Google Scholar 

Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90:12–23. https://doi.org/10.1016/j.mayocp.2014.10.007.

CAS  Article  PubMed  Google Scholar 

Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant. 2004;19:1571–5. https://doi.org/10.1093/ndt/gfh185.

CAS  Article  PubMed  Google Scholar 

Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2013;28:2570–9. https://doi.org/10.1093/ndt/gft062.

CAS  Article  PubMed  Google Scholar 

Michael B, Coyne DW, Fishbane S, Folkert V, Lynn R, Nissenson AR, et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61:1830–9. https://doi.org/10.1046/j.1523-1755.2002.00314.x.

CAS  Article  PubMed  Google Scholar 

Coyne DW, Atkinson NF Jr, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int. 2003;63:217–24. https://doi.org/10.1046/j.1523-1755.2003.00703.x.

CAS  Article  PubMed  Google Scholar 

Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999;33:464–70. https://doi.org/10.1016/s0272-6386(99)70183-6.

CAS  Article  PubMed  Google Scholar 

Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis. 2001;38:988–91. https://doi.org/10.1053/ajkd.2001.28587.

CAS  Article  PubMed  Google Scholar 

Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94:1007–14. https://doi.org/10.1002/ajh.25564.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kochhar PK, Kaundal A, Ghosh P. Intravenous iron sucrose versus oral iron in the treatment of iron deficiency anemia in pregnancy: a randomized clinical trial. J Obstet Gynaecol Res. 2013;39:504–10. https://doi.org/10.1111/j.1447-0756.2012.01982.x.

CAS  Article  PubMed  Google Scholar 

Schröder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease—a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005;100:2503–9. https://doi.org/10.1111/j.1572-0241.2005.00250.x.

CAS  Article  PubMed  Google Scholar 

Lindgren S, Wikman O, Berits R, Blom H, Eriksson A, Grännö C, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator blind, multicentre study. Scand J Gastroenterol. 2009;44:838–45. https://doi.org/10.1080/00365520902839667.

CAS  Article  PubMed  Google Scholar 

Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Nephrol Dial Transplant. 2013;28:953–64. https://doi.org/10.1093/ndt/gfs528.

CAS  Article  PubMed  Google Scholar 

Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008;101:67–73. https://doi.org/10.1016/j.ijgo.2007.10.009.

CAS  Article  PubMed  Google Scholar 

Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199(435):e1-7. https://doi.org/10.1016/j.ajog.2008.07.046.

CAS  Article  Google Scholar 

Moore RA, Gaskell H, Rose P, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disorders. 2011. https://doi.org/10.1186/1471-2326-11-4.

Article  PubMed  PubMed Central  Google Scholar 

Barish CF, Koch T, Butcher A, Morris D, Bregman DB. Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized, controlled trials. Anemia. 2012. https://doi.org/10.1155/2012/172104.

Article  PubMed  PubMed Central  Google Scholar 

Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49:2719–28. https://doi.org/10.1111/j.1537-2995.2009.02327.x.

CAS  Article  PubMed  Google Scholar 

Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110:267–78. https://doi.org/10.1097/01.AOG.0000275286.03283.18.

Article  PubMed  Google Scholar 

Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26:1599–607. https://doi.org/10.1093/ndt/gfq613.

CAS  Article  PubMed  Google Scholar 

Becuzzi N, Zimmermann R, Krafft A. Long-term efficacy of postpartum intravenous iron therapy. Biomed Res Int. 2014. https://doi.org/10.1155/2014/815437.

Article  PubMed  PubMed Central  Google Scholar 

Jose A, Mahey R, Sharma JB, Bhatla N, Saxena R, Kalaivani M, et al. Comparison of ferric carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy-randomised controlled trial. BMC Pregnancy Childbirth. 2019. https://doi.org/10.1186/s12884-019-2200-3.

Article  PubMed  PubMed Central  Google Scholar 

Onken JE, Bregman DB, Harrington RA, Morris D, Acs P, Akright B, et al. A multicenter, randomized, active-controlled study to investigate the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014;54:306–15. https://doi.org/10.1111/trf.12289.

CAS  Article  PubMed  Google Scholar 

Balakrishnan VS, Rao M, Kausz AT, Brenner L, Pereira BJG, Frigo TB, et al. Physiochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest. 2009;39:489–96. https://doi.org/10.1111/j.1365-2362.2009.02130.x.

CAS  Article  PubMed  Google Scholar 

Jahn MR, Andreasen HB, Futterer S, Nawroth T, Schunemann V, Kolb U, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78:480–91. https://doi.org/10.1016/j.ejpb.2011.03.016.

CAS  Article  PubMed  Google Scholar 

Wikstrom B, Bhandari S, Barany P, Kalra PA, Ladefoged S, Wilske J, et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol. 2011;24:589–96. https://doi.org/10.5301/JN.2011.6248.

Article  PubMed  Google Scholar 

Reinisch W, Staun M, Tandon RK, Altorjay I, Thillainayagam AV, Gratzer C, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013;108:1877–88. https://doi.org/10.1038/ajg.2013.335.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kalra PA, Bock K, Meldal M. Iron isomaltoside 1000: a new high dose option for parenteral iron therapy. Port J Nephrol Hypert. 2012;26:13–24.

Google Scholar 

Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–48. https://doi.org/10.1056/NEJMoa0908355.

CAS  Article  PubMed  Google Scholar 

Ponikowski P, van Veldhuisen D